HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals
- 124 Downloads
Direct-acting antivirals (DAAs) for the treatment of HCV have dramatically increased the rate of sustained virological response: patients not achieving sustained virological response represent a challenge and rates of late recurrent viremia are very low. We describe here the first case of a very late HCV relapse, following an atypical kinetics (characterized by a spontaneous but transient HCV clearance after an early virological relapse), in a HIV co-infected patient treated with DAAs. Optimal adherence to the therapy was well documented and a phylogenetic analysis ruled out a possible reinfection from a different HCV strain. In conclusion, our case underlines the importance of a long follow-up (> 48 weeks) after DAAs therapies in HCV–HIV co-infected patients who might benefit the most from a very rigorous virological surveillance.
KeywordsHepatitis HIV infection Recurrence Antiviral therapy IFN-free regimens Maraviroc
Compliance with ethical standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
- 8.Uojima H, Murakami S, Nakatani S, et al. Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection with liver cirrhosis. Intern Med. 2017. https://doi.org/10.2169/internalmedicine.9671-17.CrossRefPubMedPubMedCentralGoogle Scholar